分類: ACN Newswire

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. Studies have shown that aceclidine's mechanism of action (MOA) is well positioned to create a pinhole pupil effect while avoiding the impairment of distance vision called myopic shift. Aceclidine's unique pupil selective MOA, in which miosis is decoupled from myopic shift, is expected to allow it to target a broad patient population.According to publicly available information, LNZ100 received approval in the United States in July 2025 and was commercially launched in October of the same year. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. The therapy has the potential to address a significant unmet medical need in China and position itself as a best-in-class, non-invasive treatment option for presbyopia.“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”Ms. Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL, said: “We are confident that Everest Medicines’ strong commercialization capabilities will accelerate LNZ100’s market access and bring this innovative treatment to more presbyopia patients in China. Following this transaction, CORXEL’s pipeline will be entirely focused on cardiometabolic therapies. The proceeds from the transaction will enable CORXEL to accelerate the global clinical development of its innovative cardiometabolic pipeline.”Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye’s adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100 percent at the age of 52 in China. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible and invasive operation, has very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved.The NDA acceptance of LNZ100 by the National Medical Products Administration (NMPA) of the People’s Republic of China is based on the data from China Phase 3 Trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 6-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. The trial has enrolled 300 participants.The results showed that LNZ100 achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). Results also showed (all p<0.0001) a rapid onset of action, with 84% and 69% of participants achieving two-line and three-line or greater improvements, respectively, within 30 minutes of administration. The effect was also durable, with 61% and 30% of participants continuing to achieve two-line and three-line or greater improvements, respectively, at 10 hours. In addition, LNZ100 was well tolerated, and no serious treatment-related adverse events were observed in the trial.In recent years, Everest has built a proven platform for the commercialization of innovative medicines, integrating scientific and commercial insights with coordinated access, medical, marketing, and sales (A2MS). As multiple innovative products have entered the commercialization stage, the platform’s scale and synergy effects continue to strengthen. Against this backdrop, the acquisition of late-stage assets with clear clinical value and commercial potential has become an important approach for Everest to enrich its product portfolio and expand future growth opportunities. The acquisition of Greater China rights to LNZ100 further strengthens Everest Medicines’ presence in the ophthalmology and is expected to generate synergies with its existing commercialization infrastructure, supporting the continued realization of the asset’s commercial value. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年6月8日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（867.HK/8A8.SG）（「康哲藥業」）欣然宣佈，其自主研發的創新藥INHBE小核酸藥物CMS-D008注射液（「CMS-D008」）的臨床前結果在第86屆美國糖尿病協會（ADA）大會（2026年6月5-8日，美國新奧爾良）以壁報形式發佈。ADA大會作為全球糖尿病及代謝疾病領域規模最大、最具權威影響力的年度學術風向標，此次匯聚了來自世界各地的超過12,000名頂尖臨床專家、科研學者及一線醫療工作者，共同探討與見證前沿診療成果與技術創新突破。關於CMS-D008CMS-D008是康哲藥業自主研發的一款皮下注射的siRNA藥物，靶向抑制肝臟的抑制素亞基βE（INHBE）基因表達，下調INHBE編碼蛋白激活素E（Activin E）水平，從而降低脂肪代謝通路Activin E-ALK7的活化，有效減少脂質堆積，顯示出減脂不減肌、長期高質量減重的潛力。目前，CMS-D008的健康受試者I期臨床試驗正在穩步推進中；未來擬開發治療腹型肥胖以及相關代謝性疾病。CMS-D008展現出令人鼓舞的非臨床數據。本次在ADA大會發表CMS-D008的臨床前研究結果顯示，在肥胖動物模型中，CMS-D008可高效持續抑制INHBE表達，在不影響肌肉的情況下，獲得明顯的減重減脂效果，且安全性良好，有望實現健康減重。具體信息如下：標題：CMS-D008可特異性抑制INHBE mRNA，並在臨床前研究中實現了針對脂肪的減重效果摘要號：3079-LB展示形式：壁報時間：2026年6月7日01:30 PM - 02:30 PM（當地時間）地點：Hall D-E研究結果：- 在高脂飲食誘導的人源化INHBE肥胖小鼠（hINHBE DIO 小鼠）模型中，CMS-D008可顯著降低肝臟中INHBE mRNA及血清中靶蛋白Activin E的水準，進而顯著降低小鼠的體重、體脂、不同部位脂肪，且不影響小鼠的肌肉含量。- 在肥胖食蟹猴模型中，CMS-D008也可顯著降低肝臟中INHBE mRNA及血漿中靶蛋白Activin E的表達，並顯著抑制因持續攝入高脂飲食而引起的體重上升。此次研究成果入選ADA大會，體現了CMS-D008在肥胖/代謝治療領域的科學價值與臨床潛力受到國際學術界的關注。CMS-D008亦可與康哲藥業臨床開發階段的自研創新藥CMS-D005（GLP-1R/GCGR雙重激動劑）形成協同，有望實現高效的減重獲益與長期的成果維持，為患者提供更全面的治療方案。康哲藥業將自主研發作為長期發展的核心驅動力，持續深耕前沿創新領域。目前已有包括CMS-D008在內的6款擁有全球權益的自研產品進入臨床階段，另有逾20項自研專案穩步推進臨床前研究。未來，康哲藥業將繼續聚焦未被滿足的臨床需求，高效推動產品的研發與商業化進程，以更全面、創新的療法惠及廣大患者。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想了解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OTTAWA, ON, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec.The Study was completed by WSP Canada Inc. ("WSP"), one of the world's leading engineering and environmental consulting firms, under the supervision and management of IOS Geosciences Inc. ("IOS"), as part of the environmental studies supporting the advancement of Lac Knife toward future permitting and development.The AQA evaluated emissions associated with the proposed open pit mine, processing facility, tailings storage facility, stockpiles, haul roads, crushing operations, and supporting infrastructure under conservative maximum operating scenarios. Atmospheric dispersion modelling using Aeromod software, was completed in accordance with the requirements of Quebec's Reglement sur l'assainissement de l'atmosphere ("RAA") and applicable guidance from the Ministere de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs ("MELCCFP").According to WSP's conclusions, the modelling results demonstrate that predicted contaminant concentrations remain in compliance with applicable Quebec ambient air quality standards and criteria under the assessed operating conditions. WSP further concluded that all evaluated contaminants met applicable regulatory thresholds. The Study also noted that prevailing winds are predominantly directed toward the south-southeast, away from nearby public infrastructure, residences, and seasonal fishing cabins."Environmental permitting is one of the most important value-creation stages in the development of any critical mineral project," said Dean Hanisch, CEO of Focus Graphite. "The completion of the Air Quality Assessment represents another key component of the broader environmental review process and brings us closer to completing the environmental studies required to support future permitting activities. As these workstreams are completed, Lac Knife continues to become increasingly de-risked from both a technical and environmental perspective while strengthening its position as a strategic North American graphite asset."The Study evaluated a broad range of potential emissions, including particulate matter, nitrogen oxides, sulphur dioxide, carbon monoxide, crystalline silica, and various metals, using a detailed atmospheric dispersion model of the Project area and surrounding receptors based on five years of regional meteorological data.Advancing Toward Environmental Assessment CompletionThe AQA forms part of the broader environmental and permitting work program being advanced at Lac Knife and represents another important milestone toward completion of the environmental and social impact assessment ("ESIA") process. With this Study now complete, the Company is advancing the remaining key environmental workstreams, including the hydrogeological assessment and dam breach analysis, which are expected to further support permitting activities and future project development.The completion of the AQA builds on a series of technical, environmental and infrastructure achievements that continue to de-risk the Project and strengthen Lac Knife's position as a strategically important North American graphite asset. As demand for secure and reliable graphite supply continues to grow, Focus remains focused on advancing the Project through the key milestones required for future development.Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals — reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc., please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the advancement of the Lac Knife Graphite Project toward permitting readiness and future development; the completion and timing of the remaining environmental studies required to support the environmental and social impact assessment ("ESIA") process, including the hydrogeological assessment and dam breach analysis; the anticipated completion of environmental baseline, technical and permitting workstreams; the Company's ability to obtain required permits, approvals and authorizations; the anticipated benefits of completed environmental and technical studies, including the Air Quality Assessment; the timing and completion of future project milestones; the future development, construction and operation of the Lac Knife Project; the role of the Project in supporting North American and allied critical mineral supply chains; and the Company's long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300471 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1.     Sustainable & Climate TechnologyAlbacastor Technology Limited2.     AIGreen Limited 3.     Asgard Group Limited 4.     Formwork IO5.     Green Vigor Limited6.     Laputa Eco-Construction Material Company Limited7.     LeafIoT Technology Limited8.     Plasticvore Chain Ltd 9.     AI and Software Solutions Cogniser Infotech Ltd10.  D-Engraver Limited11.  Midas Analytics Limited 12.  OxGen Holdings Limited13.  Pantheon Lab Limited14.  SagaDigits Limited15.  Robotics and Microelectronics TechnologyAnlaseo Technology Limited16.  Bacbudy Limited17.  Cybercrystal Technology Co., Limited18.  Harmony SkyTech Limited19.  Oriental Materials Hong Kong Limited20.  Robocore Technology Limited21.  Health TechnologyEieling Technology Limited22.  Hong Kong Bionic Beet Robotics Limited23.  Point Fit Technology Limited 24.  UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion.  During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IRVINE, CA, June 7, 2026 - (ACN Newswire via SeaPRwire.com) - iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings a range of promotional offers and localized services to customers in Hong Kong and Southeast Asia, reflecting the company’s ongoing commitment to enhancing accessibility and customer experience across international markets.Founded in 1996, iHerb has expanded its operations to 185 countries and regions and now serves more than 11 million active users worldwide. Through its direct sourcing model and global fulfillment network, the company has focused on providing consumers with access to a broad range of international health, wellness, beauty, and personal care products.Unlike traditional cross-border retail models that often involve multiple intermediaries, iHerb purchases products directly from manufacturers and distributes them through its own warehouse network. The company stated that this approach helps improve supply chain transparency and product traceability while streamlining international delivery.As part of the 618 campaign, iHerb highlighted a selection of products from popular categories frequently purchased by consumers, including dietary supplements, personal care products, sports nutrition items, and beauty products.Among the featured products are:California Gold Nutrition LactoBif(R) 30 Billion Probiotics (CGN00965), a probiotic supplement packaged in individually sealed blister packs for convenient storage and transportation.Doctor's Best High Absorption Magnesium (DRB00087), a magnesium supplement formulated using Albion(R) TRAACS(R) chelation technology.Nature's Way Alive! Hair, Skin and Nails Gummies (NWY11534), a strawberry-flavored gummy supplement containing vitamins, collagen, and other nutritional ingredients.Metagenics OmegaGenics(R) Fish Oil EPA-DHA (MTG93873), a fish oil supplement containing EPA, DHA, and omega-3 fatty acids.ProHealth Longevity NMN Pro 1000 (PHV77904), an NMN supplement designed for adult consumers interested in wellness-focused nutritional products.The company noted that these products represent some of the diverse categories available on the platform, which currently offers nearly 3,000 brands and more than 50,000 products globally.To commemorate its 29th anniversary and the 618 Shopping Festival, iHerb announced several promotional initiatives for customers in Hong Kong and Southeast Asia:New customers can use the code WELCOME7 to receive a first-order discount.From June 11 to June 20, customers can use 618SALE26 for sitewide promotional savings.Additional regional promotions are available through the end of June using code 6HK75, subject to applicable terms and conditions.Customers in Hong Kong may qualify for free shipping on eligible orders and access local express delivery options.In addition to promotional activities, iHerb continues to expand localized services across Asian markets. Customers can shop through the company's website and mobile application, with support for local currencies and multiple payment methods, including credit cards and digital wallets.As iHerb marks its 29th anniversary, the company stated that it will continue investing in supply chain infrastructure, customer service, and regional fulfillment capabilities to support consumers seeking access to international health and wellness products.Company: iHerb, LLCContact Person: Kelly ChaiEmail: china.sm@iherb.com Website: iherb.com Telephone: (1) 951 6163600 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

塔什干，烏茲別克斯坦，2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 由香港特別行政區行政長官李家超率領、香港貿易發展局（香港貿發局）組織的商貿代表團，於6月1至3日完成以哈薩克斯坦為首站的訪問後，於6月4至5日訪問中亞之行最後一站烏茲別克斯坦首都塔什干，與當地政府及企業的高層要員會面，成功推動多領域的合作機遇。香港貿發局將全力跟進訪問期間促成的重點項目，為企業提供專業的後續商貿配對及支援服務，推動項目早日落地的同時，亦將繼續協助香港企業發掘更多國際合作機遇。單計貿發局組織的商貿代表團於訪問哈薩克斯坦及烏茲別克斯坦期間，已促成66份備忘錄及合作協議，涵蓋經貿、投資、金融、科技、航空等領域。此外，在政府層面簽訂另外15份合作文件，而非代表團成員就學術、文化等範疇亦簽署15份備忘錄，即今次訪問共達成96份備忘錄及合作協議，為香港、內地、哈薩克斯坦及烏茲別克斯坦深化經貿往來奠定良好基礎，凸顯香港作為內地企業出海的重要平台角色，並進一步推動與中亞市場的長遠合作，各方亦期望未來有更多中亞企業訪港，參與包括「一帶一路高峰論壇」、「香港國際創科展」等貿發局旗艦國際會議及展覽，把握香港作為國際商貿樞紐所帶來的機遇，深化合作。代表團在烏茲別克斯坦期間，與當地政府高層、工商機構及企業代表會面，包括烏茲別克斯坦投資、工業與貿易部、烏茲別克斯坦工商會及烏茲別克斯坦IT科技園等，深入了解當地經濟發展、市場環境及投資機遇。行政長官李家超總結中亞之行時表示：「這次訪問有三個目的：第一是進一步開拓新興市場，為推動長遠經貿發展奠定基礎。第二是加強政府與政府之間的關係往來，推進雙方更緊密合作。第三是構建樞紐對樞紐的合作模式。這次我率領75位來自香港和內地企業的商貿代表及專業人員，訪問中亞五國中兩個大國--哈薩克斯坦和烏茲別克斯坦，出席超過20場活動，考察了多個金融、創科、基建項目。訪問是成功的，有八大成果。」例如他提到，他分別與兩國的總統、總理和多位高層官員會面，雙方同意加強高層溝通聯繫及多方面協作。烏茲別克斯坦政府已同意在香港設立總領事館。此外，雙方簽訂多項協議，包括涉實質金額的項目。大家認同樞紐對樞紐的合作方向可帶來兩個區域更廣更闊的合作空間和高質量發展，雙方會增加高層互訪並支持對方的活動，共同擴大網絡。為深化經貿合作，香港特區政府與香港貿發局在烏茲別克斯坦合辦商務晚宴，吸引約230名商界領袖及主要官員出席。香港貿發局主席馬時亨教授指出：「今次中亞之行成果豐碩，再次確認了中亞國家對香港『橋樑』角色的信任。在開拓哈薩克斯坦及烏茲別克斯坦等新興市場過程中，香港憑藉國際信譽、健全制度、世界級專業服務及貿發局全球網絡平台，既是內地企業『走出去』的重要支點，亦是海外企業進入內地市場的橋頭堡，有效促進雙向投資及貿易往來。這種『引進來、走出去』的雙向流動，充分展現香港在『一帶一路』中不可替代的價值，以及貿發局作為企業雙向拓展首選平台的優勢。」是次代表團由來自香港及內地的商界領袖組成，內地企業代表來自17個省市，涵蓋金融及專業服務、物流運輸、創新科技、貿易、綠色產業以至傳媒等多個界別。本次外訪亦首次邀請新聞行業協會代表隨團，以呼應《施政報告》提出協助本地傳媒發展海外網絡、說好「香港故事」。代表團在哈薩克斯坦期間共促成43份備忘錄（MoU）及合作協議（Agreement）：1香港貿易發展局與哈薩克國家企業家協會（阿塔梅肯）2香港貿易發展局與阿斯塔納國際金融中心3香港貿易發展局與哈薩克國立科技大學4香港機場管理局與阿拉木圖國際機場5一帶一路總商會與哈薩克國家企業家協會（阿塔梅肯）6一帶一路總商會與大宗港聯數字交易股份有限公司與Eurasian Trading System Export” International Commodity Exchange (ETSE)7一帶一路總商會與 JINGSH CONSULTING LLP8香港中華廠商聯合會與哈薩克國家企業家協會（阿塔梅肯）9數碼港與阿斯塔納國際科技園10香港工業總會與哈薩克斯坦人工智能與數字發展部11香港交易及結算所有限公司與Astana International Exchange (AIX)12香港交易及結算所有限公司與阿斯塔納國際金融中心13香港科技園公司與阿斯塔納國際科技園14港深創新及科技園有限公司與阿斯塔納國際科技園15香港總商會與哈薩克國家企業家協會（阿塔梅肯）16香港律師會與哈薩克斯坦國家律師協會17中國銀行(香港)有限公司與哈薩克中國銀行與拜特雷克國家投資控股公司18中國銀行(香港)有限公司與薩姆魯克-卡澤納投資公司19博時基金（國際）有限公司與哈薩克人民儲蓄銀行20國泰航空與阿拉木圖國際機場與阿拉木圖政府（旅遊發展部）21中國國際金融股份有限公司與自由控股公司22中國國際金融股份有限公司與薩姆魯克-卡澤納投資公司23中國國際金融股份有限公司與阿斯塔納國際金融中心24中國國際金融股份有限公司與阿斯塔納航空25德勤中國與寰泰能源股份有限公司26易達資本與Dasco Capital Ltd.27易達資本與阿斯塔納國際金融中心28易達資本與江蘇關懷醫療科技（集團）有限公司與薩姆魯克-卡澤納投資公司29高鋒集團與Gas Energy Solution LLP30香港新聞行政人員協會與香港報業公會與Khabar Agency JSC31怡和控股有限公司與KIDF32佳鑫國際資源投資有限公司與哈薩克工業和建設部33科能三維技術（醫療）有限公司與哈薩克腫瘤放射研究所34電訊盈科有限公司與Kazakhtelecom35電訊盈科有限公司與Khabar Agency JSC36南華早報與阿斯塔納國際金融中心37南華早報與戈壁創投與阿斯塔納國際科技園與汗騰格裡創新中心38大豆天地農業科技有限公司與哈薩克斯坦國家糧食集團39渣打銀行與哈薩克斯坦開發銀行40渣打銀行與杭州熱聯集團股份有限公司41善水資本香港有限公司與自由控股公司42英文虎報與Freedom Horizons43沃森生物技術股份有限公司與Gold Astrum LLC代表團在烏茲別克斯坦期間共促成23份備忘錄（MoU）及合作協議（Agreement）：1香港貿易發展局與烏茲別克斯坦工商會2香港貿易發展局與烏茲別克斯坦IT科技園3香港機場管理局與Fly Khiva Group4一帶一路總商會與大宗港聯數字交易股份有限公司與中化塑料有限公司"MCHJ XK"5一帶一路總商會與烏茲別克斯坦工商會6一帶一路總商會與JINGSH CONSULTING LLP7香港中華廠商聯合會與烏茲別克斯坦工商會8香港工業總會與塔什干市政府9數碼港與烏茲別克斯坦IT科技園10香港總商會與烏茲別克斯坦工商會11香港律師會與烏茲別克斯坦共和國律師協會12甲級能源有限公司與烏茲別克斯坦扎拉夫尚黃金集團13中國國際金融股份有限公司與烏茲別克斯坦共和國對外經濟活動國家銀行14中國國際金融股份有限公司與烏茲別克斯坦共和國塔什干市政府15德勤中國與東方集團與中國國際金融股份有限公司16高鋒集團與Automated Solutions Center17善水資本香港有限公司與烏茲別克 - 阿曼投資公司18善水資本香港有限公司與CSCEC INTERNATIONAL MCHJXK（中國建築國際集團有限公司）19善水資本香港有限公司與烏茲別克斯坦共和國塔什干市政府20渣打銀行與烏茲別克斯坦共和國塔什干市政府21長春金賽藥業有限責任公司與Vita Group Farm22廣州醫藥集團有限公司與烏茲別克斯坦 ADN 醫藥工業股份公司23陝西天潤科技股份有限公司與烏茲別克斯坦共和國國家稅務委員會轄下地籍局遙感部其他非團員機構也藉此機會在教育、文化等多個領域達成合作：1甲級能源有限公司與哈薩克斯坦人工智能與數字發展部2甲級能源有限公司與自由控股公司3中國移動國際有限公司與哈郵圓通4香港城市大學與哈薩克斯坦科學與高等教育部下屬國際計劃中心5香港城市大學與薩特巴耶夫國立技術大學6香港城市大學與塔什干國立技術大學7香港教育大學與納扎爾巴耶夫大學8香港電訊與香港教育大學9香港理工大學與納扎爾巴耶夫大學10香港理工大學與El-Yurt Umidi基金會11香港理工大學與新烏茲別克斯坦大學12香港高等教育科技學院與BILIM-INNOVATION國際社會基金會13香港高等教育科技學院與L.N. Gumilyov歐亞國立大學14建銀國際與烏茲別克斯坦銀行業協會15西九文化區管理局 - 香港故宮文化博物館與烏茲別克斯坦國家歷史博物館圖片下載：https://bit.ly/4fmUpRL行政長官李家超總結中亞之行時表示：「這次訪問有三個目的：第一是進一步開拓新興市場，為推動長遠經貿發展奠定基礎。第二是加強政府與政府之間的關係往來，推進雙方更緊密合作。第三是構建樞紐對樞紐的合作模式。這次我率領75位來自香港和內地企業的商貿代表及專業人員，訪問中亞五國中兩個大國--哈薩克斯坦和烏茲別克斯坦，出席超過20場活動，考察了多個金融、創科、基建項目。訪問是成功的，有八大成果。」香港貿易發展局主席馬時亨教授聯同行政長官李家超、特區政府主要官員及代表團成員會見傳媒時表示，在行政長官率領下的中亞之行，成功為商界打開中亞市場合作的大門。香港特區政府與香港貿發局在烏茲別克斯坦合辦商務晚宴，吸引約230名商界領袖及主要官員出席。香港貿發局主席馬時亨教授於晚宴上表示：「今次中亞之行成果豐碩，再次確認了中亞國家對香港『橋樑』角色的信任。在開拓哈薩克斯坦及烏茲別克斯坦等新興市場過程中，香港憑藉國際信譽、健全制度、世界級專業服務及貿發局全球網絡平台，既是內地企業『走出去』的重要支點，亦是海外企業進入內地市場的橋頭堡，有效促進雙向投資及貿易往來。這種『引進來、走出去』的雙向流動，充分展現香港在『一帶一路』中不可替代的價值，以及貿發局作為企業雙向拓展首選平台的優勢。」代表團於烏茲別克斯坦期間促成23份備忘錄及合作協議。代表團與烏茲別克斯坦投資、工業與貿易部就兩地商貿發展以及投資機遇深入交流，期間香港貿發局主席馬時亨教授（右）與烏茲別克斯坦共和國副總理Khodjayev Jamshid Abdukhakimovich會面。代表團與烏茲別克斯坦工商會的多名代表會面，深入了解當地經濟發展、市場環境及投資機遇。代表團參觀烏茲別克斯坦IT科技園，了解當地創新科技發展。傳媒查詢新聞界如有查詢，請聯絡：香港貿易發展局傳訊及公共事務部：徐俊逸電話：(852) 2584 4395電郵：johnny.cy.tsui@hktdc.org張希汶電話：(852) 2584 4272電郵：serena.hm.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年！成立於1966年，香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業（尤其是中小企）開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong.  During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC  During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395  Email: johnny.cy.tsui@hktdc.orgSerena Cheung  Tel: (852) 2584 4272  Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 領先電子產品生產商華訊股份有限公司（「華訊」或「集團」）（股份代號：833）宣佈其位於馬來西亞檳城的生產基地正式啟用。該新設施為集團多元製造佈局策略的重要里程碑，標誌著拓展中國內地以外產能，並進一步強化東南亞的生產網絡。該檳城廠佔地約60,000平方呎，設有12條生產線，每月產能達250,000至300,000件。該廠作為原始設備製造（OEM）生產基地，主要生產銷往國際市場的工業電子產品、環境控制設備及電子電源模組。新增產能不僅擴大集團的整體製造規模，亦滿足持續增長的市場需求，為未來業務拓展提供穩固基礎。是次啟用乃承接集團於2025年完成的多項策略性部署，包括收購位於馬來西亞檳城及越南胡志明市的製造業務。進軍馬來西亞為集團首次在中國內地以外建立生產據點。集團於2025年8月完成收購檳城廠後，展開擴建及升級，引入先進設備及優化生產流程，以提升效率及品質管理水平。該設施現時生產灌溉感應器、恆溫器、保安設備及鋰電池組。華訊主席兼執行董事林賢奇先生表示：「檳城廠在推動集團建立更多元化製造網絡的策略中發揮關鍵作用。配合越南業務的拓展，我們正持續強化生產能力，提升整體供應鏈的靈活性，有助進一步增強集團的韌性與應變能力，使我們能在瞬息萬變的全球環境下更有效支援客戶業務發展。」華訊行政總裁兼執行董事林子泰先生補充指：「檳城廠正穩步提升產能，並已承接現有及新客戶的新增訂單。隨著生產線擴充及系統升級完成，產能將更趨充裕，以配合未來需求。集團亦正評估於馬來西亞設立另一個具相若產能的生產基地，推動下一階段的業務增長。」 馬來西亞官方代表、華訊董事局成員及管理層於當地新廠房舉行剪綵儀式。 華訊馬來西亞生產基地配備12條生產線，每月產能達250,000至300,000件，進一步擴大集團製造規模，滿足持續增長的客戶需求。有關華訊股份有限公司（股份代號：833）華訊股份有限公司主要從事設計及生產多款高質量且時尚的電子產品。本公司為明晟（「MSCI」）香港微型指數成份股。有關詳情，請瀏覽網頁http://www.alltronics.com.hk/。  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 君聖泰醫藥（股票代碼：2511.HK），一家專注於心腎代謝系統疾病（CKM）、開發多功能多靶點療法的創新生物醫藥公司，今日在英國格拉斯哥舉行的第63屆歐洲腎臟協會（ERA）年會上，以口頭報告的形式公佈了其核心產品HTD1801的腎臟保護最新研究結果。HTD1801是全球首創的靶向AMPK-NLRP3通路的抗炎代謝調節劑（AIMM）。在已完成的III期臨床研究（SYMPHONY-1&2）中，HTD1801顯著改善了基線eGFR為60–90 mL/min/1.73m²的2型糖尿病（T2DM）患者的腎功能。治療52周後，這些患者的eGFR平均升高了+3.08 mL/min/1.73m²（95% CI: 0.46–5.70），且未出現高濾過或體液瀦留。這些結果提示，HTD1801和現有機制藥物有差異化優勢，並具有延緩甚至逆轉疾病進程的潛力。本項研究進一步解釋了上述臨床結果。該研究由君聖泰醫藥與中國醫學科學院醫藥生物技術研究所蔣建東院士研究團隊共同完成，結果顯示，在葡萄糖及棕櫚酸誘導的足細胞損傷模型中，HTD1801可顯著提升足細胞存活率、抑制細胞凋亡；恢復足細胞關鍵結構蛋白nephrin與podocin的表達；並顯著降低代謝性炎症通路中磷酸化NF-κB及凋亡執行蛋白caspase-3水平。在糖尿病腎病（DN）模型中，HTD1801可呈劑量依賴性改善腎臟組織結構，降低腎小管損傷評分，減輕腎臟炎症及纖維化病變，並顯著降低24小時尿微量白蛋白水平。該研究系統性闡明HTD1801可抑制足細胞炎症與凋亡、穩定腎小球結構，進一步揭示了HTD1801的腎臟保護潛力，為其成為慢性腎病（CKD）及其他腎臟疾病的潛在療法提供了重要的科學依據。摘要標題：HTD1801減輕足細胞凋亡與腎小球損傷--腎臟保護機理探析報告編號：2243報告時間：2026年6月4日，星期四，上午8:15（英國夏令時間）報告形式：口頭報告報告人：Filip Surmont博士，君聖泰醫藥首席醫學官君聖泰醫藥首席醫學官Filip Surmont博士表示："此次研究首次從足細胞與腎小球層面揭示了HTD1801的腎臟保護作用。臨床研究與臨床前研究結果的高度一致，進一步證實了HTD1801在CKD或其他腎臟疾病中直擊核心病理進程的能力，彰顯了其重要治療潛力。我們將持續推進HTD1801在CKD等適應症的臨床開發，力求為全球腎病患者帶來更多創新的治療選擇。"關於HTD1801HTD1801是一款全球首創的新分子實體，旨在解決心腎代謝系統疾病（CKM）的未滿足臨床需求。HTD1801作為單一分子，是具有獨特雙機制的口服抗炎及代謝調節劑（AIMM），通過激活AMPK及抑制NLRP3炎症小體發揮其生物學活性；這種互補協同的雙機制作用可有效解決代謝問題。全球多項臨床結果驗證HTD1801具有"一藥多效"的特性，能夠為患者帶來綜合獲益，包括改善胰島素敏感性、血糖控制、血脂降低、腎臟保護、體重減輕、肝臟獲益及抗炎等。基於此，HTD1801有潛力成為CKM領域的基礎性治療藥物。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m².  Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves.                                 ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 6月4日，Synology 群暉科技於 COMPUTEX 2026 盛大展出全新技術，現場更首度亮相創新的 AI 解決方案。本次參展涵蓋新一代 DiskStation Manager（DSM）作業系統、全新 ActiveProtect 備份專用一體機、完整的影像監控生態系、大幅升級的 Synology Office 套件，以及專為個人與家庭設計的 Bee Series 私有雲產品線。「資料是我們打造一切的核心，而信任則是穩固的基石。」Synology 董事長暨執行長翁英暉表示：「從企業基礎架構到個人雲端解決方案，我們研發的每款產品，都賦予使用者對資料的絕對主權。在毫不妥協的資安防護、可靠性與隱私保障之下，協助使用者充滿信心迎向未來的挑戰。」 更加智慧的 DSM 作業系統新一代 DSM 專為 AI 及企業需求而生，系統全面支援 GPU NAS 與 AI 硬體裝置，能落實全地端的 AI 推論與治理架構；而預計推出的 DSM Agent 則能橫跨系統，提供管理建議與設計自動化的工作流程。針對企業大規模部署需求，Cluster Manager 可整合多台系統至單一管理介面，並提供工作負載轉移、服務品質（QoS）控管與集中化保護機制；雲端監控平台 Active Insight 新增大規模部署功能，可快速部署多據點架構；最後全新升級的日誌中心，則能對接企業級可觀測性（Observability）平台，進一步強化資安防護與法規合規性。提升保護能力的 ActiveProtect Manager 2.0ActiveProtect Manager（APM） 2.0 擴大保護範圍，延伸至 AWS EC2、Azure VM、Proxmox、Nutanix AHV 與 Google Workspace，並支援跨平台還原，協助企業在混合雲與虛擬環境中保持資安韌性。本次還加入主動式威脅防禦，整合了 AI 驅動的異常與惡意程式偵測機制。同時，ActiveProtect 產品線迎來最新機種 DP5200 ，為企業帶來更高彈性的部署選擇。全新影像監控門禁控制、DVA 伺服器與混合雲監控Synology 影像監控生態系持續茁壯，首先展出門禁控制解決方案，包含 AC100 門禁控制器與 AR 系列讀卡機，並公開即將推出的 DC 系列半球型攝影機。再來智慧影像分析伺服器 DVA 系列導入了 AI 語意搜尋，與人員重識別（Re-identification）路徑追蹤等功能，有效提升監控效率。為使生態系更臻完善，Surveillance365 主打雲端監控服務（VSaaS），並能無縫整合地端的 Surveillance Station，為企業打造專屬的混合雲平台，完美實現遠端與多據點的安全監控。ChatPlus 與 Meet 強化溝通效率Synology Office Suite 正式增添生力軍 ChatPlus 與 Meet，為企業帶來具備細緻權限與管控功能的企業級通訊工具。兩款套件皆內建 AI 驅動的語音轉文字與翻譯功能，大幅提升團隊的協作效率，並確保所有資料完全落地、由企業 100% 掌控手中。專為個人與家庭打造的 Bee Series 私有雲生態系BeeStation與BeeStation Plus產品線，現在提供更豐富的容量與規格選擇，滿足多元的儲存需求。另外，使用者現在可透過BeeCamera功能，搭配Synology Cameras在BeeStation Plus上輕鬆展開監控；而基於macOS與Windows系統的 Synology Deep Search服務，則利用AI技術，提供高效的地端搜尋體驗，讓使用者在兼顧隱私的前提之下，精準找出個人裝置中的任何內容。欲了解更多Synology群暉科技產品和解決方案詳情或有任何需求， 歡迎至Synology群暉科技官網或聯繫 hk.event@synology.comMedia Contacts :Contact Us: https://www.synology.com/zh-hk/company/contact_us Synology Marketing & PR Specialist, Sandra Soh : sandrasoh@synology.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley  aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com